A Prompt REstart Study of Renin-Angiotensin System Inhibitors After Acute Kidney Injury

Starting soon · Phase 4

Conditions studied: Acute Kidney Injury

In brief

The goal of this pilot clinical trial is to learn if early restart of renin-angiotensin system inhibitor (RASi) medications is feasible and well-tolerated in hospitalized patients with acute kidney injury (AKI). Researchers will compare early RASi restart to usual care. Study participants will restart RASi per study protocol, obtain a lab test in 1-2 weeks if RASi restarted in the hospital and not collected as part of routine care, and answer questions at the 90-day follow-up.

Key facts

Study ID

NCT07734636

Run by

University of California, San Francisco

People needed

60

Starts

2026-08-01

Expected to finish

2029-03-01

Last updated by the study team

2026-07-29

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Age ≥ 18 years
• Pre-admission RASi use for Class I indication (e.g., heart failure, kidney disease)
• RASi stopped in the setting of AKI (defined by ≥1.5x baseline SCr)
• AKI in recovery (defined by a decrease in SCr by ≥0.3mg/dL from peak)

You may not qualify if…

• RASi allergy or contraindication (i.e., angioedema, bilateral renal artery stenosis)
• Ongoing dialysis requirement
• Pregnant or breastfeeding
• Prisoner
• Palliative or hospice care involvement
• Unable to consent
• No enteral route of medication administration
• Clinician judgment

Where it is running

• University of California, San Francisco — San Francisco, California, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.